"CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced positive results from a multisite U.S. study that showed that its FirstSight blood test is highly accurate in detecting colorectal cancer, as well as advanced adenomas."
"CellMax Life and Sebela Pharmaceuticals said on Tuesday that they have signed a strategic development and agreement to complete commercial development of CellMax's FirstSight liquid biopsy assay...Sebela plans to seek 510(k) approval for the assay from the US Food and Drug Administration and will commercialize the test in the US."